Connor A Emdin1, Tom Callender1, Jun Cao2, Kazem Rahimi3. 1. George Institute for Global Health, Oxford Martin School, University of Oxford, 34 Broad Street, Oxford, UK. 2. George Institute for Global Health, Oxford Martin School, University of Oxford, 34 Broad Street, Oxford, UK National Heart and Lung Institute, Imperial College London, London, UK. 3. George Institute for Global Health, Oxford Martin School, University of Oxford, 34 Broad Street, Oxford, UK kazem.rahimi@georgeinstitute.ox.ac.uk.
Abstract
AIMS: High blood pressure is known to be associated with future risk of atrial fibrillation. Whether such risks can be reduced with antihypertensive therapy is less clear. We conducted a systematic review and meta-analysis of large-scale randomized trials that have reported the effect of antihypertensive agents on atrial fibrillation. METHODS AND RESULTS: MEDLINE was searched for randomized trials published between 1966 and February 2014. Randomized, controlled trials were eligible for inclusion if they tested an antihypertensive agent and reported atrial fibrillation as an outcome. Atrial fibrillation, reported as trial outcome or adverse event, and study characteristics were extracted by investigators. In 27 trials with 214 763 randomized participants and 9929 events of atrial fibrillation, pooled using inverse-variance weighted fixed effects meta-analysis, antihypertensive therapy reduced the risk of atrial fibrillation by 10% [risk ratio (RR) 0.90; 95% confidence interval (CI) 0.86, 0.94]. However, the proportional effects differed significantly between trials (P < 0.001 for heterogeneity). In trials that included patients with no prior heart disease, or patients with coronary artery disease but no heart failure, no significant effects were found (RR 1.02; CI 0.88, 1.18 and RR 0.95; CI 0.89, 1.01, respectively). Conversely, proportional effects were larger in trials that predominantly included patients with heart failure (RR 0.81; CI 0.74, 0.87). When classes of medication were compared against each other, no significant differences in effects on atrial fibrillation were observed. CONCLUSIONS: Antihypertensive therapy reduces the risk of atrial fibrillation modestly but benefits appear to be larger in patients with heart failure, with no clear evidence of benefit in patients without heart failure. Previous suggestions of class-specific effects could not be confirmed in this more comprehensive analysis. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: High blood pressure is known to be associated with future risk of atrial fibrillation. Whether such risks can be reduced with antihypertensive therapy is less clear. We conducted a systematic review and meta-analysis of large-scale randomized trials that have reported the effect of antihypertensive agents on atrial fibrillation. METHODS AND RESULTS: MEDLINE was searched for randomized trials published between 1966 and February 2014. Randomized, controlled trials were eligible for inclusion if they tested an antihypertensive agent and reported atrial fibrillation as an outcome. Atrial fibrillation, reported as trial outcome or adverse event, and study characteristics were extracted by investigators. In 27 trials with 214 763 randomized participants and 9929 events of atrial fibrillation, pooled using inverse-variance weighted fixed effects meta-analysis, antihypertensive therapy reduced the risk of atrial fibrillation by 10% [risk ratio (RR) 0.90; 95% confidence interval (CI) 0.86, 0.94]. However, the proportional effects differed significantly between trials (P < 0.001 for heterogeneity). In trials that included patients with no prior heart disease, or patients with coronary artery disease but no heart failure, no significant effects were found (RR 1.02; CI 0.88, 1.18 and RR 0.95; CI 0.89, 1.01, respectively). Conversely, proportional effects were larger in trials that predominantly included patients with heart failure (RR 0.81; CI 0.74, 0.87). When classes of medication were compared against each other, no significant differences in effects on atrial fibrillation were observed. CONCLUSIONS: Antihypertensive therapy reduces the risk of atrial fibrillation modestly but benefits appear to be larger in patients with heart failure, with no clear evidence of benefit in patients without heart failure. Previous suggestions of class-specific effects could not be confirmed in this more comprehensive analysis. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marin; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu Journal: Eur J Prev Cardiol Date: 2016-11-04 Impact factor: 7.804
Authors: Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marín; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu Journal: Europace Date: 2017-02-01 Impact factor: 5.214
Authors: Asad Ali; Muhammad Abu Zar; Ahmad Kamal; Amber E Faquih; Chandur Bhan; Waleed Iftikhar; Muhammad Bilal Malik; Malik Qistas Ahmad; Nouman Safdar Ali; Shahzad Ahmed Sami; Fnu Jitidhar; Abbas M Cheema; Annum Zulfiqar Journal: Cureus Date: 2018-08-29
Authors: Estefanía Lozano-Velasco; Rosemary Wangensteen; Andrés Quesada; Carlos Garcia-Padilla; Julia A Osorio; María Dolores Ruiz-Torres; Amelia Aranega; Diego Franco Journal: PLoS One Date: 2017-12-01 Impact factor: 3.240
Authors: Connor A Emdin; Simon G Anderson; Gholamreza Salimi-Khorshidi; Mark Woodward; Stephen MacMahon; Terrence Dwyer; Kazem Rahimi Journal: Int J Epidemiol Date: 2017-02-01 Impact factor: 7.196
Authors: Domingo Orozco-Beltran; Jose A Quesada; Vicente Bertomeu-Gonzalez; Jose M Lobos-Bejarano; Jorge Navarro-Perez; Vicente F Gil-Guillen; Luis Garcia Ortiz; Adriana Lopez-Pineda; Angel Castellanos-Rodriguez; Angela Lopez-Domenech; Antonio Francisco J Cardona-Llorens; Concepcion Carratala-Munuera Journal: Sci Rep Date: 2020-03-16 Impact factor: 4.379
Authors: Matthew C Hyman; Michael G Levin; Dipender Gill; Venexia M Walker; Marios K Georgakis; Neil M Davies; Francis E Marchlinski; Scott M Damrauer Journal: Hypertension Date: 2021-01-04 Impact factor: 10.190